Telix Pharmaceuticals (TLX1N) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TLX1N Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Telix

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TLX1N Stock 12 Month Forecast

Average Price Target

$307.37

▲(1.59% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is $307.37 with a high forecast of $377.11 and a low forecast of $218.97. The average price target represents a 1.59% change from the last price of $302.55.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"217":"$217","378":"$378","257.25":"$257.3","297.5":"$297.5","337.75":"$337.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":377.11060296,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$377.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":307.365416176,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$307.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":218.96744688,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$218.97</span>\n  </div></div>","useHTML":true}}],"tickPositions":[217,257.25,297.5,337.75,378],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,302.55,308.2854309969231,314.02086199384615,319.7562929907692,325.4917239876923,331.22715498461537,336.9625859815385,342.6980169784615,348.43344797538464,354.1688789723077,359.9043099692308,365.63974096615385,371.3751719630769,{"y":377.11060296,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,302.55,302.9204166289231,303.29083325784615,303.6612498867692,304.03166651569234,304.4020831446154,304.77249977353847,305.14291640246154,305.5133330313846,305.88374966030767,306.2541662892308,306.62458291815386,306.99499954707693,{"y":307.365416176,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,302.55,296.1205728369231,289.69114567384617,283.26171851076924,276.8322913476923,270.4028641846154,263.9734370215385,257.54400985846155,251.11458269538463,244.6851555323077,238.25572836923078,231.82630120615386,225.39687404307693,{"y":218.96744688,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":302.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$377.11

Average Price Target$307.37

Lowest Price Target$218.97

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Laura Sutcliffe

Citi

$377.11

Buy

24.64%

Upside

Reiterated

07/29/26

Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), Impedimed Limited (IPDQF)

Chris Cooper

J.P. Morgan

$296.82

Buy

-1.89%

Downside

Reiterated

07/23/26

J.P. Morgan Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

Steven Wheen

Jarden

$256.68

Buy

-15.16%

Downside

Reiterated

07/22/26

Jarden Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

Shane Storey

Canaccord Genuity

$364.95

Buy

20.62%

Upside

Reiterated

07/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and CSL (Other OTC: CMXHF)

David Stanton

Jefferies

$352.78

Buy

16.60%

Upside

Reiterated

07/21/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

John Hester

Bell Potter

$231.13

Buy

-23.61%

Downside

Reiterated

07/21/26

Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

David Bailey

Morgan Stanley

$272.49→$290.74

Buy

-3.90%

Downside

Reiterated

07/21/26

Telix Pharmaceuticals (TLPPF) Gets a Buy from Morgan Stanley

Craig Wong-Pan

RBC Capital

$218.97

Hold

-27.63%

Downside

Reiterated

07/21/26

David Dai

UBS

$377.11

Buy

24.64%

Upside

Reiterated

07/01/26

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (NYSE: EVMN) and Telix Pharmaceuticals (Other OTC: TLPPF)

Tara Bancroft

TD Cowen

$243.3

Buy

-19.58%

Downside

Reiterated

02/19/26

Telix: Dual-Product PSMA Strategy and Cash-Generating Diagnostics Base Support Buy Rating and Multibillion-Dollar Therapeutics Upside

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$274.93

Buy

-9.13%

Downside

Reiterated

10/15/25

Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett

Andrew Paine

CLSA

$295

Buy

-2.50%

Downside

Reiterated

10/03/25

CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Laura Sutcliffe

Citi

$377.11

Buy

24.64%

Upside

Reiterated

07/29/26

Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), Impedimed Limited (IPDQF)

Chris Cooper

J.P. Morgan

$296.82

Buy

-1.89%

Downside

Reiterated

07/23/26

J.P. Morgan Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

Steven Wheen

Jarden

$256.68

Buy

-15.16%

Downside

Reiterated

07/22/26

Jarden Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

Shane Storey

Canaccord Genuity

$364.95

Buy

20.62%

Upside

Reiterated

07/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and CSL (Other OTC: CMXHF)

David Stanton

Jefferies

$352.78

Buy

16.60%

Upside

Reiterated

07/21/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

John Hester

Bell Potter

$231.13

Buy

-23.61%

Downside

Reiterated

07/21/26

Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

David Bailey

Morgan Stanley

$272.49→$290.74

Buy

-3.90%

Downside

Reiterated

07/21/26

Telix Pharmaceuticals (TLPPF) Gets a Buy from Morgan Stanley

Craig Wong-Pan

RBC Capital

$218.97

Hold

-27.63%

Downside

Reiterated

07/21/26

David Dai

UBS

$377.11

Buy

24.64%

Upside

Reiterated

07/01/26

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (NYSE: EVMN) and Telix Pharmaceuticals (Other OTC: TLPPF)

Tara Bancroft

TD Cowen

$243.3

Buy

-19.58%

Downside

Reiterated

02/19/26

Telix: Dual-Product PSMA Strategy and Cash-Generating Diagnostics Base Support Buy Rating and Multibillion-Dollar Therapeutics Upside

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$274.93

Buy

-9.13%

Downside

Reiterated

10/15/25

Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett

Andrew Paine

CLSA

$295

Buy

-2.50%

Downside

Reiterated

10/03/25

CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Telix Pharmaceuticals

3 Months

David StantonJefferies

Success Rate

14/19 ratings generated profit

Average Return

+23.44%

Copying David Stanton's trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +23.44% per trade.

1 Year

Steven WheenJarden

Success Rate

19/26 ratings generated profit

Average Return

+46.94%

Copying Steven Wheen's trades and holding each position for 1 Year would result in 73.08% of your transactions generating a profit, with an average return of +46.94% per trade.

2 Years

Steven WheenJarden

Success Rate

16/26 ratings generated profit

Average Return

+87.27%

Copying Steven Wheen's trades and holding each position for 2 Years would result in 61.54% of your transactions generating a profit, with an average return of +87.27% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLX1N Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TLX1N has received 13 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. TLX1N average Analyst price target in the past 3 months is 307.37.

Each month's total comprises the sum of three months' worth of ratings.

TLX1N Financial Forecast

TLX1N Earnings Forecast

Next quarter’s earnings estimate for TLX1N is $0.34 with a range of $0.34 to $0.34. The previous quarter’s EPS was -$0.21. TLX1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year TLX1N has Performed in-line its overall industry.

TLX1N Sales Forecast

Next quarter’s sales forecast for TLX1N is $4.24B with a range of $4.24B to $4.24B. The previous quarter’s sales results were $7.64B. TLX1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year TLX1N has Performed in-line its overall industry.

TLX1N Stock Forecast FAQ

What is MX:TLX1N’s average 12-month price target, according to analysts?

Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 307.37.

What is MX:TLX1N’s upside potential, based on the analysts’ average price target?

Telix Pharmaceuticals Ltd. has 1.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Telix Pharmaceuticals Ltd. a Buy, Sell or Hold?

Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Telix Pharmaceuticals Ltd.’s share price target?

The average share price target for Telix Pharmaceuticals Ltd. is 307.37. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $377.11 ,and the lowest forecast is $218.97. The average share price target represents 1.59% Increase from the current price of $302.55.

What do analysts say about Telix Pharmaceuticals Ltd.?

Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Telix Pharmaceuticals Ltd.?

To buy shares of MX:TLX1N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Telix Pharmaceuticals (TLX1N) Stock Forecast & Price Target

TLX1N Analyst Ratings

TLX1N Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Telix Pharmaceuticals

TLX1N Analyst Recommendation Trends

TLX1N Financial Forecast

TLX1N Earnings Forecast

TLX1N Sales Forecast

TLX1N Stock Forecast FAQ

Detailed List of Analyst Forecasts